Edition:
India

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

198.90DKK
22 Jun 2018
Change (% chg)

kr.2.10 (+1.07%)
Prev Close
kr.196.80
Open
kr.196.00
Day's High
kr.199.45
Day's Low
kr.195.05
Volume
126,495
Avg. Vol
417,371
52-wk High
kr.444.00
52-wk Low
kr.158.55

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic Q1 EBIT Loss Widens To DKK 173 Million
Thursday, 24 May 2018 

May 24 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST THREE MONTHS OF 2018.OUTLOOK FOR 2018 MAINTAINED.Q1 EBIT LOSS DKK 173 MILLION VERSUS LOSS DKK 3 MILLION YEAR AGO.OUTLOOK FOR 2018 MAINTAINED.Q1 REVENUE DKK 11 MILLION VERSUS DKK 198 MILLION YEAR AGO."FINANCIAL RESULTS FOR Q1 WERE IN LINE WITH OUR EXPECTATIONS".  Full Article

Bavarian Nordic Announces Positive Results Of Pivotal Phase 3 Study Of Imvamune Smallpox Vaccine
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Bavarian Nordic A/S ::BAVARIAN NORDIC ANNOUNCES POSITIVE RESULTS OF PIVOTAL PHASE 3 STUDY OF IMVAMUNE® SMALLPOX VACCINE.BLA FILING EXPECTED IN SECOND HALF OF 2018 WITH FAST TRACK DESIGNATION.SAYS ‍STUDY ACHIEVED BOTH OF ITS PRIMARY ENDPOINTS​.SECOND POSITIVE PHASE 3 DEMONSTRATING THE SAFETY AND EFFICACY OF IMVAMUNE AND FINAL STUDY REQUIRED FOR LICENSURE, AS AGREED WITH FDA.  Full Article

‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Bavarian Nordic A/S ::‍BAVARIAN NORDIC ANNOUNCES EXERCISE OF CLINICAL OPTION BY US GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE​.BAVARIAN NORDIC A/S SAYS ‍CONTRACT OPTION IS EXPECTED TO BE REVENUE RECOGNIZED BETWEEN 2018 AND 2022​.BAVARIAN NORDIC- OPTION, WHICH REPRESENTS ABOUT $37 MILLION OF TOTAL CONTRACT OF UP TO $539 MILLION, WILL COVER DEVELOPMENT COSTS ASSOCIATED WITH PHASE 3 STUDY​.ANNOUNCEMENT DOES NOT AFFECT COMPANY'S EXPECTATIONS FOR FINANCIAL RESULTS FOR 2017​.  Full Article

Bavarian Nordic Q3 EBIT at DKK 432 million
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BAVARIAN NORDIC A/S ::‍OUTLOOK FOR 2017 MAINTAINED​.Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO.Q3 REVENUE DKK 734.3‍​ MILLION VERSUS DKK 452.3 MILLION YEAR AGO.  Full Article

Bavarian Nordic wins big smallpox vaccine order for U.S. government
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - BAVARIAN NORDIC A/S :SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT.INITIAL BASE AWARD SECURES ADDITIONAL IMVAMUNE BULK CONTRACT OF USD 100 MILLION.CONTRACT INCLUDES INITIAL OPTIONS VALUED AT USD 439 MILLION.POTENTIAL VALUE OF INITIAL BASE AND OPTIONAL AWARDS IS IN EXCESS OF $539 MILLION.BAVARIAN NORDIC-AWARD OF CONTRACT FROM BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY FOR PROCUREMENT OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE.  Full Article

Bavarian Nordic launches share buy-back program to hedge incentive scheme obligations
Thursday, 18 May 2017 

May 18 (Reuters) - Bavarian Nordic A/S :REG-BAVARIAN NORDIC LAUNCHES SHARE BUY-BACK PROGRAM TO HEDGE INCENTIVE SCHEME OBLIGATIONS.COMPANY INTENDS TO BUY BACK 12,156 OF ITS OWN SHARES..  Full Article

Bavarian Nordic names Christopher Heery Chief Medical Officer
Wednesday, 28 Sep 2016 

Bavarian Nordic A/S : Appoints Christopher Heery, M.D., as Chief Medical Officer .Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute.  Full Article

Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million
Wednesday, 17 Aug 2016 

Bavarian Nordic A/S : H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago . Q2 revenue 116.6 million crowns versus 389.1 million crowns year ago . Q2 EBIT loss 54.0 million crowns versus profit 125.0 million crowns year ago .Maintains its financial expectations for 2016.  Full Article